September 29, 2021 Pfizer adds to gene therapy woes But another safety scare for the big pharma’s Duchenne muscular dystrophy project could be good news for Sarepta.
June 07, 2019 Vertex’s second transformation: Duchenne time The cystic fibrosis player does deals with Crispr and Exonics to launch itself into a highly competitive rare disease area.
